Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
(1) Objective: At Week 26, to assess the effect on HbA1c of 15 mg ertugliflozin as compared with placebo. Hypothesis: At Week 26, the mean reduction from baseline in HbA1c for 15 mg ertugliflozin is greater than that for placebo. (2) Objective: At Week 26, to assess the effect on HbA1c of 5 mg ertugliflozin as compared with placebo. Hypothesis: At Week 26, the mean reduction from baseline in HbA1c for 5 mg ertugliflozin is greater than that for placebo. (3) Objective: To assess the safety and tolerability of ertugliflozin.
Inclusion criteria
- Type 2 diabetes mellitus